Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

NASDAQ LPCN opened at $3.35 on Friday. The stock’s 50-day moving average is $3.63 and its 200-day moving average is $4.50. Lipocine has a one year low of $2.91 and a one year high of $11.79. The firm has a market cap of $17.92 million, a P/E ratio of -4.41 and a beta of 1.43.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC raised its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.